Etivelcabtagene Erigedleucel

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of allogeneic, off-the-shelf (OTS), universal transcription activator-like effector nuclease (TALEN)-engineered T-lymphocytes that have been genetically modified to express chimeric antigen receptors (CARs) specific for the tumor-associated antigens (TAAs) cluster of differentiation 20 (CD20) and CD22, with potential immunostimulating and antineoplastic activities. Using TALEN technology, the T-cell receptor (TCR) alpha chain (TRAC) and CD52 genes are inactivated. Upon administration, etivelcabtagene erigedleucel specifically recognizes and induces selective toxicity in CD20- and CD22-expressing tumor cells. CD20 and CD22 are overexpressed in certain hematologic malignancies. Inactivation of the CD52 gene makes the CAR-T cells UCART20x22 resistant to anti-CD52 monoclonal antibody treatment that is used during preconditioning regimen to enhance the expansion and persistence of the CAR-T cells. The knockout of TRAC eliminates TCR expression and is intended to abrogate the potential induction of graft-versus-host disease (GvHD) by the CAR-T cells.

**Synonyms:** - Allogeneic Anti-CD20/CD22 Universal CAR T Cells UCART20x22 - Allogeneic Anti-CD20/CD22 Universal CAR-T Cells UCART20x22 - Allogeneic Anti-CD20/CD22 Universal CAR-expressing T-cells UCART20x22 - Allogeneic Anti-CD20/CD22 Universal CAR-expressing T-lymphocytes UCART20x22 - CAR-T Cells UCART20x22 - ETIVELCABTAGENE ERIGEDLEUCEL - UCART 20x22 - UCART-20x22 - UCART20x22